Patents by Inventor Thomas A. Waldmann

Thomas A. Waldmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RECOMBINANT VACCINE VIRUSES EXPRESSING IL-15 AND METHODS OF USING THE SAME
    Publication number: 20140377306
    Abstract: The invention is directed to compositions capable of augmenting the immunogenicity of a vaccine. The composition, or adjuvant, is administered to a mammal in need thereof in sequential or concurrent combination with a vaccine antigen. In one preferred aspect, the adjuvant is provided in the form of a recombinant poxvirus vector, such as a vaccinia virus vector, which comprises a nucleic acid sequence encoding IL-15.
    Type: Application
    Filed: January 15, 2014
    Publication date: December 25, 2014
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health & Human Services
    Inventors: Liyanage P. Perera, Thomas A. Waldmann, Sang-Kon Oh, Jay A. Berzofsky
  • Recombinant vaccine viruses expressing IL-15 and methods using the same
    Patent number: 8663622
    Abstract: The invention is directed to compositions capable of augmenting the immunogenicity of a vaccine. The composition, or adjuvant, is administered to a mammal in need thereof in sequential or concurrent combination with a vaccine antigen. In one preferred aspect, the adjuvant is provided in the form of a recombinant poxvirus vector, such as a vaccinia virus vector, which comprises a nucleic acid sequence encoding IL-15.
    Type: Grant
    Filed: December 15, 2003
    Date of Patent: March 4, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Liyanage P. Perera, Thomas A. Waldmann, Sang-Kon Oh, Jay A. Berzofsky
  • Method for treating malignancy and autoimmune disorders in humans using tac antibodies
    Patent number: 7094404
    Abstract: The present invention relates to a method for treating conditions associated with elevated levels of Tac-positive cells, including malignancy and autoimmune disorders and for preventing allograft rejection. 90Y-Conjugated anti-Tac or Ricin A conjugated anti-Tac and optionally unconjugated anti-Tac antibodies are employed to treat the above conditions. Clinical therapies have been designed to treat immune diseases and lymphomas in patients using conjugated anti-Tac antibodies.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 22, 2006
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventor: Thomas A. Waldmann
  • Interleukin 2 receptor and applications thereof
    Patent number: 5833983
    Abstract: The present invention is related to the field of receptor molecules and complexes. More particularly, the present invention is related to a new polypeptide receptor for interleukin-2 having a molecular weight of about 70-75,000, which is a component of the high affinity IL-2 receptor, antibodies against this new polypeptide, and recombinant interleukins capable of binding to the new receptor. Various applications of the p70-75 receptor, the anti-p70-75 antibodies and IL-2W.sub.1 and IL2W.sub.2 have also been described.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 10, 1998
    Assignee: The United States of America as represented by the Secretary of Dept. of Health and Human Services
    Inventors: Thomas A. Waldmann, Warren J. Leonard